DiscGenics receives FDA designation for injectable disc cell therapy treatment
Click Here to Manage Email Alerts
DiscGenics Inc. has received FDA regenerative medicine advanced therapy designation for its injectable disc cell therapy for the treatment of patients with symptomatic lumbar degenerative disc disease, according to a press release.
Injectable disc cell therapy (IDCT) has the potential to increase disc volume, improve low back pain and decrease pain medication usage in patients with lumbar degenerative disc disease, according to the release.
“This designation represents a critical validation of our novel approach to utilizing a manufactured live progenitor cell population derived from donated adult human intervertebral disc tissue to treat disc degeneration,” Flagg Flanagan, chair and CEO of DiscGenics, said in the release. “As committed stewards of this technology, we look forward to partnering with the FDA to expedite our drug development program and to ultimately realizing the potential of IDCT to address the unmet medical needs of millions of patients with this painful and debilitating condition,” Flanagan said.
Read more about
Click Here to Manage Email Alerts